TL;DR
Researchers have developed a novel "hyBRET" biosensor platform that combines the strengths of FRET and BRET imaging. This platform allows for the visualization of cellular signaling in live animals with unprecedented flexibility, overcoming limitations of previous FRET-only biosensors and enabling applications from optogenetics to drug screening and in vivo pharmacodynamics.
What Problem Does This Paper Address?
Genetically encoded biosensors are powerful tools for visualizing cellular signaling. Two main types exist: FRET (fluorescence resonance energy transfer) and BRET (bioluminescence resonance energy transfer). FRET biosensors offer high spatial resolution but suffer from background noise, phototoxicity, and incompatibility with optogenetic tools. BRET biosensors, on the other hand, have low background signals ideal for drug screening, but historically have faced challenges with low signal intensity and short substrate half-lives, hindering their widespread adoption for complex biological questions. The core problem this paper addresses is the limitation of existing FRET biosensors and the difficulty in transforming them into robust BRET biosensors, thereby restricting their application in advanced imaging and in vivo studies.
Methods
The key innovation is a simple, one-step protocol to create "hyBRET" biosensors by fusing a bioluminescent protein (RLuc8) to the C-terminus of existing intramolecular FRET biosensors. This fusion protein acts as a donor for both FRET and BRET energy transfer.
- FRET-BRET Hybridization: The researchers fused RLuc8 (a bright luciferase mutant) to the CFP (cyan fluorescent protein) component of established FRET biosensors, creating hyBRET biosensors. This allows the biosensor to function in both FRET mode (using CFP as donor) and BRET mode (using RLuc8 as donor).
- Energy Transfer Analysis: Sophisticated spectral analysis techniques (linear unmixing, curve fitting) were employed to quantify the energy transfer rates between the different fluorescent and bioluminescent proteins in both FRET and BRET modes.
- Optogenetic Integration: The hyBRET biosensors were tested for compatibility with optogenetic tools (e.g., CRY2 system) to control signaling pathways with light, demonstrating their ability to function alongside light-activated systems.
- High-Throughput Screening: The hyBRET biosensors were adapted for use with luminescence microplate readers, enabling high-throughput screening of drug effects on cellular signaling.
- In Vivo Imaging: The platform was validated for non-invasive imaging of signaling dynamics in live mice, both in tumor xenografts and in whole-body imaging, utilizing a long-acting substrate for bioluminescence.
Datasets
Not explicitly discussed as "datasets" in the traditional machine learning sense. The study utilizes:
- Cell lines: HeLa, HCT116, PC9, 4T1, and Lenti-X 293T cells were used for in vitro experiments.
- Animal models: Xenograft tumor models (HeLa and 4T1 cells in mice) and transgenic mice expressing hyBRET biosensors were used for in vivo studies.
Key Insights and Ideas
- Bridging FRET and BRET: The hyBRET approach elegantly bridges the gap between FRET and BRET, inheriting the high resolution of FRET and the low background and optogenetic compatibility of BRET.
- Universal Transformation: The simple fusion of RLuc8 to CFP-based FRET biosensors proved to be a versatile method for transforming a wide range of biosensors (for kinases, GTPases, etc.) into functional hyBRET biosensors.
- Optogenetics Synergy: The incompatibility of FRET biosensors with optogenetic tools due to spectral overlap is a major hurdle. hyBRET biosensors overcome this by using bioluminescence, opening new avenues for light-controlled cellular studies.
- In Vivo Potential Realized: The development of a long-acting bioluminescent substrate (diacetyl coelenterazine-h) was crucial for enabling sustained, non-invasive in vivo imaging of signaling dynamics, a significant advancement for pharmacodynamics studies.
- NanoLuc Limitations: Surprisingly, attempts to use the even brighter NanoLuc luciferase in place of RLuc8 did not yield functional biosensors responsive to stimuli, suggesting that NanoLuc might interfere with the biosensor's conformational changes.
Key Results
- Successful Transformation: The hyBRET biosensor retained the dynamic range of its FRET counterpart and exhibited comparable performance in BRET mode.
- Optogenetic Compatibility: Light-induced activation of signaling pathways (ERK, S6K, Ras) was successfully monitored using hyBRET biosensors in conjunction with optogenetic tools.
- High-Throughput Screening Efficiency: The hyBRET assay in microplate readers demonstrated high Z' values (e.g., 0.93), indicating suitability for high-throughput screening.
- In Vivo Pharmacodynamics: The MEK inhibitor PD-0325901's effect on ERK activity was successfully monitored non-invasively in tumors and whole bodies of mice, with drug effects detectable within minutes.
- Transgenic Mouse Lines: Stable transgenic mouse lines expressing hyBRET biosensors were generated, showing no apparent anomalies and enabling whole-body imaging of signaling dynamics.
Limitations and Future Work
- NanoLuc Challenges: The inability to create functional hyBRET biosensors with NanoLuc is a limitation, suggesting that further optimization is needed for this brighter luciferase.
- Substrate Half-Life: While diacetyl coelenterazine-h improved in vivo imaging duration, continuous infusion was still required for prolonged studies, highlighting the need for even longer-lasting substrates.
- In Vivo Signal Heterogeneity: Variations in BRET signals across different tumor locations or organs in vivo were observed, attributed to potential heterogeneity in ERK activity, hypoxia, or light scattering, necessitating careful interpretation of spatial data.
- Future Directions: The authors suggest expanding the platform to other FRET biosensors, developing brighter and longer-lasting bioluminescent substrates, and further exploring the use of hyBRET biosensor transgenic mice for drug development and disease modeling.
Summary updated